Literature DB >> 22958475

Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality.

Marjolein C H van der Meulen, Adele L Boskey.   

Abstract

Bisphosphonates are highly effective agents for reducing osteoporotic fractures in women and men, decreasing fracture incidence at the hip and spine up to 50%. In a small subset of patients, however, these agents have recently been associated with 'atypical femoral fractures' (AFFs) in the subtrochanteric region or the diaphysis. These fractures have several atypical characteristics, including occurrence with minimal trauma; younger age than typical osteoporotic fractures; occurrence at cortical, rather than cancellous sites; early radiographic appearance similar to that of a stress fracture; transverse fracture pattern rather than the familiar spiral or transverse-oblique morphologies; initiation on the lateral cortex; and high risk of fracture on the contralateral side, at the same location as the initial fracture. Fracture is a mechanical phenomenon that occurs when the loads applied to a structure such as a long bone exceed its load-bearing capacity, either due to a single catastrophic overload (traumatic failure) or as a result of accumulated damage and crack propagation at sub-failure loads (fatigue failure). The association of AFFs with no or minimal trauma suggests a fatigue-based mechanism that depends on cortical cross-sectional geometry and tissue material properties. In the case of AFFs, bisphosphonate treatment may alter cortical tissue properties, as these agents are known to alter bone remodeling. This review discusses the use of bisphosphonates, their effects on bone remodeling, mechanics and tissue composition, their significance as an effective therapy for osteoporosis, and why these agents may increase fracture risk in a small population of patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22958475      PMCID: PMC3580578          DOI: 10.1186/ar4013

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


  67 in total

1.  Letter to the editor: the effect of long-term alendronate treatment on cortical thickness of the proximal femur.

Authors:  Joyce S B Koh; Alvin C M Ng; Meng Ai Png; Tet Sen Howe
Journal:  Clin Orthop Relat Res       Date:  2011-12       Impact factor: 4.176

Review 2.  Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.

Authors:  Teresita Bellido; Lilian I Plotkin
Journal:  Bone       Date:  2010-08-18       Impact factor: 4.398

Review 3.  The relationship between the chemistry and biological activity of the bisphosphonates.

Authors:  Frank H Ebetino; Anne-Marie L Hogan; Shuting Sun; Maria K Tsoumpra; Xuchen Duan; James T Triffitt; Aaron A Kwaasi; James E Dunford; Bobby L Barnett; Udo Oppermann; Mark W Lundy; Alan Boyde; Boris A Kashemirov; Charles E McKenna; R Graham G Russell
Journal:  Bone       Date:  2011-04-09       Impact factor: 4.398

Review 4.  The role of the collagen matrix in skeletal fragility.

Authors:  Deepak Vashishth
Journal:  Curr Osteoporos Rep       Date:  2007-06       Impact factor: 5.096

5.  Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.

Authors:  Erich Durchschlag; Eleftherios P Paschalis; Ruth Zoehrer; Paul Roschger; Peter Fratzl; Robert Recker; Roger Phipps; Klaus Klaushofer
Journal:  J Bone Miner Res       Date:  2006-10       Impact factor: 6.741

6.  Stress fracture in military recruits: gender differences in muscle and bone susceptibility factors.

Authors:  T J Beck; C B Ruff; R A Shaffer; K Betsinger; D W Trone; S K Brodine
Journal:  Bone       Date:  2000-09       Impact factor: 4.398

7.  Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study.

Authors:  Roland D Chapurlat; Monique Arlot; Brigitte Burt-Pichat; Pascale Chavassieux; Jean Paul Roux; Nathalie Portero-Muzy; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

8.  Age-related changes in the collagen network and toughness of bone.

Authors:  X Wang; X Shen; X Li; C Mauli Agrawal
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

9.  Use of FTIR spectroscopic imaging to identify parameters associated with fragility fracture.

Authors:  Samuel Gourion-Arsiquaud; Dan Faibish; Elizabeth Myers; Lyudmila Spevak; Juliet Compston; Anthony Hodsman; Elizabeth Shane; Robert R Recker; Elizabeth R Boskey; Adele L Boskey
Journal:  J Bone Miner Res       Date:  2009-09       Impact factor: 6.741

10.  Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis.

Authors:  Lisa-Ann Fraser; Kelly N Vogt; Jonathan D Adachi; Lehana Thabane
Journal:  Ther Clin Risk Manag       Date:  2011-05-09       Impact factor: 2.423

View more
  19 in total

Review 1.  Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Authors:  Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer
Journal:  J Bone Miner Res       Date:  2016-01       Impact factor: 6.741

2.  Identifying Novel Clinical Surrogates to Assess Human Bone Fracture Toughness.

Authors:  Mathilde Granke; Alexander J Makowski; Sasidhar Uppuganti; Mark D Does; Jeffry S Nyman
Journal:  J Bone Miner Res       Date:  2015-06-08       Impact factor: 6.741

3.  Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture.

Authors:  Yoichi Iizuka; Rumi Takechi; Haku Iizuka; Takuya Omodaka; Kenji Takagishi
Journal:  Skeletal Radiol       Date:  2016-07-11       Impact factor: 2.199

Review 4.  Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspects.

Authors:  Barbara M Misof; Nadja Fratzl-Zelman; Eleftherios P Paschalis; Paul Roschger; Klaus Klaushofer
Journal:  Bonekey Rep       Date:  2015-02-11

5.  "Atypical" atypical femur fractures and use of bisphosphonates.

Authors:  Denise M van de Laarschot; Matthijs P Somford; Agnes Jager; Edwin H Oei; P Koen Bos; M Carola Zillikens
Journal:  Clin Cases Miner Bone Metab       Date:  2017-02-10

Review 6.  Atypical femoral fractures: a review of the literature.

Authors:  Pingal A Desai; Parth A Vyas; Joseph M Lane
Journal:  Curr Osteoporos Rep       Date:  2013-09       Impact factor: 5.096

7.  Fructus Ligustri Lucidi (FLL) ethanol extract increases bone mineral density and improves bone properties in growing female rats.

Authors:  Ying Lyu; Xin Feng; Pengling Zhao; Zhenghao Wu; Hao Xu; Yuehui Fang; Yangfeng Hou; Liya Denney; Yajun Xu; Haotian Feng
Journal:  J Bone Miner Metab       Date:  2013-12-21       Impact factor: 2.626

Review 8.  Changes in the degree of mineralization with osteoporosis and its treatment.

Authors:  Paul Roschger; Barbara Misof; Eleftherios Paschalis; Peter Fratzl; Klaus Klaushofer
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

Review 9.  The fragile elderly hip: mechanisms associated with age-related loss of strength and toughness.

Authors:  Jonathan Reeve; Nigel Loveridge
Journal:  Bone       Date:  2014-01-09       Impact factor: 4.398

10.  Dichotomous location of 160 atypical femoral fractures.

Authors:  Veronika A Koeppen; Jörg Schilcher; Per Aspenberg
Journal:  Acta Orthop       Date:  2013-11-29       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.